For years, oncologists have been baffled by why checkpoint inhibitors work for some cancer patients and not others. This challenge has made it difficult for these immunotherapies to be widely used since it isn’t easy to predict who will benefit and yet the treatments are currently very expensive .
Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company developing targeted genetic medicine delivery therapies, announced that the U.S. Food and Drug Administration granted Fast Track designation to CLD-201 (SuperNova), its allogeneic adipose stem-cell loaded oncolytic virus for treating soft tissue sarcoma. The designation provides opportunities for expedited development, including priority review and accelerated approval. CLD-201, which received IND clearance in April, will enter a Phase 1 trial evaluating safety and efficacy in sarcoma, triple-negative breast cancer, and head and neck squamous cell carcinoma. Chief Medical Officer Guy Travis Clifton, M.D., said the milestone validates CLD-201’s potential to deliver durable, transformational treatment for patients with advanced tumors.
Looking for insights into the US markets in the middle of the day on Monday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company developing targeted genetic medicine delivery platforms, will implement a 1-for-12 reverse stock split of its common stock effective August 5, 2025. Shares will begin trading on a split-adjusted basis on the NYSE American under the existing ticker “CLDI,” with a new CUSIP of 320703 408. The reverse split, approved by shareholders on July 9 and ratified by the board on July 11, is intended to optimize market dynamics, expand investor appeal and align trading conditions with shareholder interests. Every 12 pre-split shares will convert into one post-split share, with fractional shares rounded up to the nearest whole share at the participant level. The action will proportionately adjust outstanding options, warrants and equity plan shares but will not affect the par value or the number of authorized shares.
Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotech company developing targeted genetic medicine therapies, will host an investor webinar on July 24, 2025, at 4:15 p.m. ET. Led by CEO Eric Poma, Ph.D., the event will showcase Calidi’s RedTail(TM) platform, a systemically delivered viral therapy designed to treat metastatic tumors by evading immune detection. Preclinical data on lead candidate CLD-401 showed tumor elimination and immune memory activation. The company is progressing toward an IND filing and pursuing strategic pharma partnerships to support commercialization. A Q&A session will follow the presentation.
The US market is yet to commence its session on Friday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
Lung cancer, one of the most common types of cancer, has for a long time been known to largely develop among smokers. However, recent studies have established that around one quarter of people diagnosed with lung cancer has never smoked. This has baffled the scientific community as there was no clear explanation why such a significant proportion of lung cancer patients didn’t have a history of smoking.
Findings from a recent study suggest that the herpes virus can be modified into an effective treatment for some types of advanced melanoma. Conducted by researchers from the University of Southern California’s Keck Medicine of USC, the clinical trial looked into the feasibility of deploying cancer-fighting herpes virus against advanced skin cancers.
Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotech innovator, announced its inclusion in an editorial by NetworkNewsWire titled “Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers.” The article highlights Calidi’s next-generation platform, which uses engineered viruses to deliver genetic therapies directly to primary and metastatic tumors. While oncology is the company’s initial focus, it is also evaluating applications in autoimmune disorders, underscoring its broader therapeutic potential. The editorial emphasizes Calidi’s role in addressing the rising global cancer burden and advancing transformative treatment options.
After the conclusion of the US market's regular session on Thursday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.
